Real-World Treatment Patterns and Patient reported outcome in COPD (REMIND)

Trial Identifier:	D5980R00080
Sponsor:	AstraZeneca
NCTID::	NCT05903989
Start Date:	September 2023
Primary Completion Date:	October 2023
Study Completion Date:	October 2023
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Japan	Osaka, Japan

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.